PAVmed receives 180-day extension to regain Nasdaq compliance

PAVmed announced that it received a written notice from the Nasdaq Stock Market granting the company a 180-day extension to regain compliance with Nasdaq’s $1.00 minimum bid price requirement as set forth in Nasdaq Listing Rule 5550(a)(2). The company was first notified by Nasdaq on December 29, 2022, and originally was given until June 27, 2023, to regain compliance. The company now has until December 26, 2023, to meet the requirement.